158 related articles for article (PubMed ID: 25908608)
1. An update on human immunodeficiency virus vaccine preparedness studies.
Dhalla S
J Med Microbiol; 2015 Jul; 64(7):731-738. PubMed ID: 25908608
[TBL] [Abstract][Full Text] [Related]
2. Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies.
Dhalla S; Poole G
Vaccine; 2011 Aug; 29(35):5850-9. PubMed ID: 21740947
[TBL] [Abstract][Full Text] [Related]
3. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies.
Dhalla S; Poole G
AIDS Care; 2011 Nov; 23(11):1430-47. PubMed ID: 21722022
[TBL] [Abstract][Full Text] [Related]
4. HIV vaccine preparedness studies in the non-organization for economic co-operation and development (non-OECD) countries.
Dhalla S; Nelson KE; Singer J; Poole G
AIDS Care; 2009 Mar; 21(3):335-48. PubMed ID: 18781449
[TBL] [Abstract][Full Text] [Related]
5. Barriers to participation in actual HIV vaccine trials.
Dhalla S; Poole G
Curr HIV Res; 2013 Apr; 11(3):238-45. PubMed ID: 23721228
[TBL] [Abstract][Full Text] [Related]
6. Age and sex or gender (sex/gender) and HIV vaccine preparedness.
Dhalla S
Psychol Health Med; 2016 Jun; 21(4):505-524. PubMed ID: 26515031
[TBL] [Abstract][Full Text] [Related]
7. Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention.
Dhalla S; Poole G
Hum Vaccin Immunother; 2014; 10(7):1974-84. PubMed ID: 25424807
[TBL] [Abstract][Full Text] [Related]
8. Does message framing predict willingness to participate in a hypothetical HIV vaccine trial: an application of Prospect Theory.
Evangeli M; Kafaar Z; Kagee A; Swartz L; Bullemor-Day P
AIDS Care; 2013; 25(7):910-4. PubMed ID: 23216424
[TBL] [Abstract][Full Text] [Related]
9. Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa.
Middelkoop K; Myer L; Mark D; Mthimunye SP; Smit J; Wood R; Bekker LG
J Adolesc Health; 2008 Jul; 43(1):8-14. PubMed ID: 18565432
[TBL] [Abstract][Full Text] [Related]
10. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand.
Jenkins RA; Chinaworapong S; Morgan PA; Ruangyuttikarn C; Sontirat A; Chiu J; Michael RA; Nitayaphan S; Khamboonruang C
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):171-7. PubMed ID: 9637582
[TBL] [Abstract][Full Text] [Related]
11. Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa.
Otwombe KN; Sikkema KJ; Dietrich J; de Bruyn G; van der Watt M; Gray GE
J Acquir Immune Defic Syndr; 2011 Oct; 58(2):211-8. PubMed ID: 21765362
[TBL] [Abstract][Full Text] [Related]
12. HIV vaccine preparedness studies in the organization for economic co-operation and development (OECD) countries.
Dhalla S; Woods R; Strathdee SA; Patrick DM; Hogg RS
AIDS Care; 2007 Oct; 19(9):1118-27. PubMed ID: 17851989
[TBL] [Abstract][Full Text] [Related]
13. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE
AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082
[TBL] [Abstract][Full Text] [Related]
14. High HIV-1 prevalence, risk behaviours, and willingness to participate in HIV vaccine trials in fishing communities on Lake Victoria, Uganda.
Kiwanuka N; Ssetaala A; Mpendo J; Wambuzi M; Nanvubya A; Sigirenda S; Nalutaaya A; Kato P; Nielsen L; Kaleebu P; Nalusiba J; Sewankambo NK
J Int AIDS Soc; 2013 Jul; 16(1):18621. PubMed ID: 23880102
[TBL] [Abstract][Full Text] [Related]
15. Motivators to participation in actual HIV vaccine trials.
Dhalla S; Poole G
AIDS Behav; 2014 Feb; 18(2):263-77. PubMed ID: 23736885
[TBL] [Abstract][Full Text] [Related]
16. HIV/AIDS Vaccines: 2018.
Robinson HL
Clin Pharmacol Ther; 2018 Dec; 104(6):1062-1073. PubMed ID: 30099743
[TBL] [Abstract][Full Text] [Related]
17. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya.
Jackson DJ; Martin HL; Bwayo JJ; Nyange PM; Rakwar JP; Kashonga F; Mandaliya K; Ndinya-Achola JO; Kreiss JK
AIDS; 1995 Nov; 9(11):1279-83. PubMed ID: 8561982
[TBL] [Abstract][Full Text] [Related]
18. Recruitment using respondent driven sampling, risk behaviors assessment and willingness of young female sex workers (18-25 years) in Dar Es Salaam, Tanzania to participate in HIV vaccine trials.
Mbunda T; Tarimo EAM; Bakari M; Sandström E; Kulane A
BMC Public Health; 2019 Nov; 19(1):1537. PubMed ID: 31796002
[TBL] [Abstract][Full Text] [Related]
19. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
[TBL] [Abstract][Full Text] [Related]
20. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation.
Buchbinder SP; Metch B; Holte SE; Scheer S; Coletti A; Vittinghoff E
J Acquir Immune Defic Syndr; 2004 May; 36(1):604-12. PubMed ID: 15097304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]